WO2025098502 - THERAPEUTIC USE OF PHARMACEUTICAL COMPOSITION COMPRISING INSULIN DERIVATIVE
National phase entry:
Publication Number
WO/2025/098502
Publication Date
15.05.2025
International Application No.
PCT/CN2024/131090
International Filing Date
08.11.2024
Title **
[English]
THERAPEUTIC USE OF PHARMACEUTICAL COMPOSITION COMPRISING INSULIN DERIVATIVE
[French]
UTILISATION THÉRAPEUTIQUE D'UNE COMPOSITION PHARMACEUTIQUE COMPRENANT UN DÉRIVÉ D'INSULINE
[Chinese]
包含胰岛素衍生物的药物组合物的治疗用途
Applicants **
GAN & LEE PHARMACEUTICALS CO., LTD.
Inventors
GAN, Zhongru
HAO, Chunyue
ZHAO, Jing
CHEN, Wei
Priority Data
202311480982.4
08.11.2023
CN
202410702342.1
02.06.2024
CN
202411090791.1
09.08.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2515 | |
| EPO | Filing, Examination, Granting | 22276 | |
| Japan | Filing, Examination, Granting | 2772 | |
| South Korea | Filing, Examination, Granting | 3533 | |
| USA | Filing, Examination, Granting | 7740 |
Total:
38,836
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to the use of a pharmaceutical combination or pharmaceutical composition containing two active ingredients, an insulin derivative and a rapid-acting insulin, in the treatment of diabetes mellitus. Provided is a method for treating or preventing metabolic syndrome and type II diabetes in a subject in need thereof by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof. Also provided is a kit comprising the description for performing treatment according to the method.[French]
La présente invention concerne l'utilisation d'une combinaison pharmaceutique ou d'une composition pharmaceutique contenant deux principes actifs, un dérivé d'insuline et une insuline à action rapide, dans le traitement du diabète sucré. Est prévu un procédé de traitement ou de prévention du syndrome métabolique et du diabète de type II chez un sujet en ayant besoin par l'administration d'un composé de formule (I) ou d'un sel pharmaceutiquement acceptable de celui-ci. Est également prévu un kit comprenant la description pour effectuer un traitement selon le procédé.[Chinese]
涉及含有胰岛素衍生物和速效胰岛素两种活性成分的药物组合或药物组合物在治疗糖尿病中的用途。提供一种通过施用式(I)化合物或其药学上可接受的盐治疗或预防有需要的受试者代谢综合征以及II型糖尿病的方法。还提供包含根据所述方法进行治疗的说明书的药盒。